Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 4:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,888 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Standard of care agent Clear all
Terminated Phase 1 Interventional Results available

KZR-261 in Subjects With Advanced Solid Malignancies

NCT05047536
View directory record Official record
Conditions
Advanced/Metastatic Solid Tumor
Interventions
KZR-261
Drug
Lead sponsor
Kezar Life Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
12
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Results available

Conivaptan for the Reduction of Cerebral Edema in Intracerebral Hemorrhage- A Safety and Tolerability Study

NCT03000283
View directory record Official record
Conditions
Cerebral Hemorrhage, Cerebral Edema, Intracerebral Hemorrhage, Stroke
Interventions
Conivaptan
Drug
Lead sponsor
Jesse Corry
Other
Eligibility
19 Years to 79 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 2 Interventional

Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer

NCT03037437
View directory record Official record
Conditions
Hepatocellular Cancer
Interventions
Sorafenib (SOR), Hydroxychloroquine (HCQ)
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 100 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Results available

Short-Term Outcome of N-Carbamylglutamate in the Treatment of Acute Hyperammonemia

NCT01599286
View directory record Official record
Conditions
Propionic Acidemia, Type I and/or Type II, Methylmalonic Acidemia, Carbamoyl-Phosphate Synthase I Deficiency Disease, Ornithine Carbamoyltransferase Deficiency
Interventions
Carbaglu, Placebo
Drug
Lead sponsor
Mendel Tuchman
Other
Eligibility
1 Week to 99 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 1 Interventional

Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT02543879
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
Interventions
FT-1101, Azacitidine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2023 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 1 Interventional

Safety Study of Nelfinavir + Cisplatin + Pelvic Radiation Therapy to Treat Cervical Cancer

NCT01485731
View directory record Official record
Conditions
Cervical Cancer
Interventions
Nelfinavir, Cisplatin, Pelvic External Beam Radiation Therapy, Brachytherapy, Pharmacokinetic Sampling, Cervical Biopsy, Pelvic Examination, Pap Smear, Audiogram, Proctoscopy, Cytoscopy, Renal Ultrasound, CT Scan, Whole Body PET/CT Scan
Drug · Radiation · Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 5, 2026, 4:55 AM EDT
Terminated Not applicable Interventional

Domperidone for Relief of Gastrointestinal Disorders

NCT00761254
View directory record Official record
Conditions
Gastroparesis, GERD, Esophagitis, Dyspepsia, Chronic Idiopathic Constipation, Nausea, Vomiting
Interventions
Domperidone
Drug
Lead sponsor
Carle Physician Group
Individual
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Results available

A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma

NCT03890666
View directory record Official record
Conditions
Asthma
Interventions
Albuterol eMDPI DS, albuterol
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
13 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Stockton, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Not applicable Interventional

OPTIONS: A Patient-Centered HIV Prevention Decision Aid for PrEP Uptake for Women With Substance Use in Treatment Settings

NCT03651453
View directory record Official record
Conditions
HIV Infections, Substance Abuse
Interventions
Decision aid, Standard care
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Oct 5, 2026, 4:55 AM EDT
Terminated Not applicable Interventional

Effects of a Novel Dietary Intervention on Body Composition After Laparoscopic Gastric Bypass Surgery

NCT01041261
View directory record Official record
Conditions
Obesity, Morbid Obesity
Interventions
BariatrX Essentials 360 Treatment
Dietary Supplement
Lead sponsor
MetaProteomics LLC
Industry
Eligibility
25 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Results available

NMDA Antagonists in Bipolar Depression

NCT01833897
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Standard of Care, Ketamine, D-cycloserine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis

NCT03296345
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-Occlusive Crisis
Interventions
Ketamine
Drug
Lead sponsor
UCSF Benioff Children's Hospital Oakland
Other
Eligibility
10 Years to 25 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Oct 5, 2026, 4:55 AM EDT
Active, not recruiting Phase 2 Interventional

HOT: HIPEC in Ovarian Cancer as Initial Treatment

NCT02124421
View directory record Official record
Conditions
Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma
Interventions
Cytoreductive Surgery (CRS), Adjuvant Chemotherapy, Questionnaire, Hyperthermic intraperitoneal chemotherapy, Carboplatin, Paclitaxel, Cisplatin
Procedure · Drug · Other
Lead sponsor
Mercy Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 1 Interventional Results available

Daylight Photodynamic Therapy for Actinic Keratosis

NCT03322293
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Aminolevulinic Acid Topical 20% Topical Solution, BLU-U blue light phototherapy illuminator
Drug · Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 5, 2026, 4:55 AM EDT
Completed No phase listed Observational

Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

NCT03205696
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Antiretrovirals
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
12 Years to 24 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
3
States / cities
Los Angeles, California • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 5, 2026, 4:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

NCT03366844
View directory record Official record
Conditions
Breast Cancer
Interventions
Pembrolizumab, RT Boost
Drug · Radiation
Lead sponsor
Stephen Shiao
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Detection of Liver Fibrosis With Magnetic Resonance Imaging (MRI)

NCT01600105
View directory record Official record
Conditions
Chronic Liver Disease
Interventions
Perfusion MRI
Drug
Lead sponsor
Bachir Taouli
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 5, 2026, 4:55 AM EDT
Recruiting No phase listed Observational

Prospective Analysis of Spinal Epidural Abscess

NCT05464251
View directory record Official record
Conditions
Spinal Epidural Abscess
Interventions
Prospective chart review of subjects diagnosed with spinal epidural abscess
Other
Lead sponsor
Francis Farhadi
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Phase 4 Interventional Results available

Periarticular Bupivacaine + Meloxicam ER Solution Versus Standard Practice During Total Knee Arthroplasty

NCT05188053
View directory record Official record
Conditions
Total Knee Arthroplasty
Interventions
HTX-011, ropivacaine , epinephrine , ketorolac diluted in sodium chloride
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 5, 2026, 4:55 AM EDT
Recruiting Phase 1Phase 2 Interventional

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945
View directory record Official record
Conditions
Multiple Myeloma
Interventions
AZD0305, Elranatamab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
9
States / cities
Duarte, California • Irvine, California • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 5, 2026, 4:55 AM EDT
Terminated Phase 2 Interventional Results available

Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)

NCT01925612
View directory record Official record
Conditions
Lymphoma, B-cell, Lymphoma, Large B-cell, Diffuse
Interventions
brentuximab vedotin, rituximab, vincristine, cyclophosphamide, prednisone, doxorubicin
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Transforming Care and Payment Priorities for Vulnerable Families

NCT03416712
View directory record Official record
Conditions
Social Stress
Interventions
Screening survey and accompanying handout for resources
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 5, 2026, 4:55 AM EDT
Completed Not applicable Interventional Results available

Hypofractionated Radiation Therapy to Improve Immunotherapy Response in Non-Small Cell Lung Cancer

NCT03035890
View directory record Official record
Conditions
Non Small Cell Lung Cancer Metastatic
Interventions
Radiation, Immuno-Therapeutic Agent
Radiation · Drug
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 1, 2025 · Synced Oct 5, 2026, 4:55 AM EDT